These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 33429417)

  • 1. Comparison chart: SGLT2 inhibitors.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):e2-e4. PubMed ID: 33429417
    [No Abstract]   [Full Text] [Related]  

  • 2. Ertugliflozin for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):70-72. PubMed ID: 29667948
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
    [No Abstract]   [Full Text] [Related]  

  • 4. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2022 Nov; 64(1663):177-184. PubMed ID: 36384763
    [No Abstract]   [Full Text] [Related]  

  • 5. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 7. In brief: Canagliflozin and lower limb amputations.
    Med Lett Drugs Ther; 2020 Sep; 62(1607):152. PubMed ID: 32960870
    [No Abstract]   [Full Text] [Related]  

  • 8. Sotagliflozin (Inpefa) for heart failure.
    Med Lett Drugs Ther; 2023 Jul; 65(1681):114-116. PubMed ID: 37460142
    [No Abstract]   [Full Text] [Related]  

  • 9. Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes.
    Med Lett Drugs Ther; 2023 Aug; 65(1683):130-132. PubMed ID: 37651295
    [No Abstract]   [Full Text] [Related]  

  • 10. Empagliflozin (Jardiance) for heart failure.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):177-178. PubMed ID: 33438858
    [No Abstract]   [Full Text] [Related]  

  • 11. In brief: Expanded heart failure indication for empagliflozin (Jardiance).
    Med Lett Drugs Ther; 2022 Apr; 64(1648):57. PubMed ID: 35436772
    [No Abstract]   [Full Text] [Related]  

  • 12. Empagliflozin (Jardiance) for heart failure with reduced ejection fraction.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):171-172. PubMed ID: 35085205
    [No Abstract]   [Full Text] [Related]  

  • 13. In brief: Expanded heart failure indication for dapagliflozin (Farxiga).
    Med Lett Drugs Ther; 2023 Jun; 65(1679):101-102. PubMed ID: 37339090
    [No Abstract]   [Full Text] [Related]  

  • 14. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
    Davidson JA
    Postgrad Med; 2019 May; 131(4):251-260. PubMed ID: 30929540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin: A Review in Type 2 Diabetes.
    Deeks ED; Scheen AJ
    Drugs; 2017 Sep; 77(14):1577-1592. PubMed ID: 28836175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
    Shi FH; Li H; Yue J; Jiang YH; Gu ZC; Ma J; Lin HW
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors.
    Engelhardt K; Ferguson M; Rosselli JL
    Ann Pharmacother; 2021 Apr; 55(4):543-548. PubMed ID: 32808541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ertugliflozin for the treatment of type 2 diabetes.
    Sharma R; Razdan K; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.